Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1401 - 1422 of 1422

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 600 of 600

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1476 - 1500 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: Recommendations		Jan 15, 2019	Health Technology Review	Optimal Use	Completed	OP0538-000 / CT0001
Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma	media:document:d00ebe66-c3ca-4630-a5c9-9db0789e0f05 media:document:d878e503-9902-4b9a-b462-1c08b76ea345 media:document:db2f1690-ae45-427b-926d-e7e0b29a66b6	Jan 15, 2019	Health Technology Review	Optimal Use	Completed	OP0538-000 / CT0001
nitisinone	SR0538_cdr_complete_MDK_Nitisinone_Apr_27_18_e.pdf SR0538_MDK_Nitisinone_CL_Report.pdf SR0538_MDK_Nitisinone_PE_Report.pdf SR0538_MDK_Nitisinone_PI_Submissions.pdf	Jan 14, 2019	Reimbursement Review		Complete	SR0538-000
Levodopa / carbidopa (Drug Plan Submission)	SR0557_Duodopa_Aug_24-18.pdf SR0557_DuodopaFWG_CL_Report.pdf SR0557_DuodopaFWG_PE_Report.pdf SR0557_Duodopa_PI_Submissions.pdf si0001-duodopa-drug-implementation-advice.pdf	Jan 14, 2019	Reimbursement Review		Complete	SR0557-000
Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details	pcodr_provfund_10158_bevacizumab_mvasi_mcrc_nsclc.pdf 10158MVASI_CADTHBiosimilarSummaryDossier_FINAL_14Jan2019.pdf	Jan 14, 2019	Reimbursement Review		Complete	PC0158-000
Detection and Diagnosis of Sepsis in Rural and Remote Areas: An Environmental Scan		Jan 9, 2019	Health Technology Review	Environmental Scan	Completed	ES0327-000
Rivaroxaban	SR0569 Xarelto - Confidential Final CDEC Recommendation (redacted)_for posting.pdf SR0569_Xarelto_CL_Report.pdf SR0569_Xarelto_PE_Report.pdf	Jan 3, 2019	Reimbursement Review		Complete	SR0569-000
ozenoxacin	SR0553_Ozanex_Oct-26-18.pdf SR0553_Ozanex_CL_Report.pdf SR0553_Ozanex_PE_Report.pdf SR0553_Ozanex_PI_Submissions.pdf	Dec 21, 2018	Reimbursement Review		Complete	SR0553-000
bictegravir/emtricitabine/tenofovir alafenamide	SR0567 Biktarvy - CDEC Final Recommendation October 29, 2018.pdf SR0567_Biktarvy_CL_Report.pdf SR0567_Biktarvy_PE_Report.pdf SR0567_Biktarvy_PI_Submissions.pdf	Dec 21, 2018	Reimbursement Review		Complete	SR0567-000
dexamethasone	SR0535_Ozurdex_Oct-26-18.pdf SR0535_Ozurdex _CL_Report.pdf SR0535_Ozurdex_PE_Report .pdf SR0535_Ozurdex_PI_Submissions.pdf	Dec 21, 2018	Reimbursement Review		Complete	SR0535-000
sebelipase alfa	SR0544 Kanuma - CDEC Final Recommendation September 28, 2018.pdf SR0544_Kanuma_CL_Report.pdf SR0544_Kanuma_PE_Report.pdf SR0544_Kanuma_PI_Submissions.pdf si0003-kanuma-cadth-drug-implementation-advice.pdf	Dec 21, 2018	Reimbursement Review		Complete	SR0544-000
Tapentadol Hydrochloride	SR0563_Nucynta - CDEC Final Recommendation October 25, 2018.pdf SR0563_Nucynta_CL_Report.pdf SR0563_Nucynta_PE_Report.pdf SR0563_Nucynta_PI_Submissions.pdf	Dec 21, 2018	Reimbursement Review		Complete	SR0563-000
Opdivo for Hepatocellular Carcinoma – Details	pcodr_provfund_nivolumab_opdivo_hcc.pdf pcodr_nivolumab_opdivo_hcc_fn_rec.pdf pcodr_nivolumab_opdivo_hcc_fn_cgr.pdf pcodr_nivolumab_opdivo_hcc_fn_egr.pdf pcodr_nivolumab_opdivo_hcc_in_rec.pdf pcodr_nivolumab_opdivo_hcc_pagfdk.pdf pcodr_nivolumab_opdivo_hcc_bmsc.pdf pcodr_nivolumab_opdivo_hcc_clnfdk.pdf pcodr_nivolumab_opdivo_hcc_coi_pt.pdf pcodr_nivolumab_opdivo_hcc_coi_cln.pdf	Dec 14, 2018	Reimbursement Review		Complete	PC0134-000
Perjeta-Herceptin Combo Pack for Early Breast Cancer – Details	pcodr_provfund_10127perjeta-herceptin-combo_ebc.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_rec.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_cgr.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_egr.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_in_rec.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_pagfdk.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_hlr.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_ptfdk.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_clnfdk.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_coi_pt.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_coi_cln.pdf	Dec 14, 2018	Reimbursement Review		Complete	PC0127-000
CADTH Pharmaceutical Reviews Update — Issue 4		Dec 13, 2018	Reimbursement Review	Pharmaceutical Review Update
lumacaftor/ivacaftor	SR0559 Orkambi - CDEC Final Recommendation October 4, 2018.pdf SR0559_Orkambi_CL_Report.pdf SR0559_Orkambi_PE_Report.pdf SR0559_Orkambi_PI_Submissions.pdf	Nov 19, 2018	Reimbursement Review		Complete	SR0559-000
filgrastim		Nov 19, 2018	Reimbursement Review		Cancelled	SE0596-000
Engaging with History Taking for Adverse Childhood Experiences in Care: A Rapid Qualitative Review	Engaging with History Taking for Adverse Childhood Experiences in Care: A Rapid…	Nov 19, 2018	Health Technology Review	Rapid Review	Completed	RC1045-000
Opdivo in combo with Yervoy for Renal Cell Carcinoma – Details	pcodr_profund_10132opdivo-yervoy_rcc.pdf pcodr_opdivo_yervoy_rcc_fn_rec.pdf pcodr_opdivo_yervoy_rcc_fn_cgr.pdf pcodr_opdivo_yervoy_rcc_fn_egr.pdf pcodr_opdivo_yervoy_rcc_in_rec.pdf pcodr_opdivo_yervoy_rcc_pagfdk.pdf pcodr_opdivo_yervoy_rcc_fdk_bms.pdf pcodr_opdivo_yervoy_rcc_clnfdk.pdf pcodr_opdivo_yervoy_rcc_coi_pt.pdf pcodr_opdivo_yervoy_rcc_coi_cln.pdf	Nov 16, 2018	Reimbursement Review		Complete	PC0132-000
Gazyva for Follicular Lymphoma (previously untreated) – Details	pcodr_provfund_10126obinutuzumab_gazyva_fl_preun.pdf pcodr_obinutuzumab_gazyva_fl_preun_fn_rec.pdf pcodr_obinutuzumab_gazyva_fl_preun_fn_cgr.pdf pcodr_obinutuzumab_gazyva_fl_preun_fn_egr.pdf pcodr_obinutuzumab_gazyva_fl_preun_in_rec.pdf pcodr_obinutuzumab_gazyva_fl_preun_pagfdk.pdf pcodr_obinutuzumab_gazyva_fl_preun_fdk_hlr.pdf pcodr_obinutuzumab_gazyva_fl_preun_clnfdk.pdf pcodr_obinutuzumab_gazyva_fl_preun_coi_pt.pdf pcodr_obinutuzumab_gazyva_fl_preun_coi_cln.pdf	Nov 16, 2018	Reimbursement Review		Complete	PC0126-000
Erleada for Castrate Resistant Prostate Cancer - Details	pcodr_provfund_apalutamide_erleada_nm-cprc.pdf pcodr_apalutamide_erleada_crpc_fn_rec.pdf pcodr_apalutamide_erleada_crpc_fn_cgr.pdf pcodr_apalutamide_erleada_crpc_fn_egr.pdf pcodr_apalutamide_erleada_crpc_in_rec.pdf pcodr_apalutamide_erleada_crpc_pagfdk.pdf pcodr_apalutamide_erleada_crpc_fdk_janssen.pdf pcodr_apalutamide_erleada_crpc_ptfdk.pdf pcodr_apalutamide_erleada_crpc_clnfdk.pdf pcodr_apalutamide_erleada_crpc_coi_pt.pdf pcodr_apalutamide_erleada_crpc_coi_cln.pdf	Nov 16, 2018	Reimbursement Review		Complete	PC0133-000
Beleodaq for Peripheral T-Cell Lymphoma – Detail		Oct 24, 2018	Reimbursement Review		Withdrawn	PC0139-000
Dapagliflozin	cdr_SR0445_Forxiga.pdf SR0445_complete_Forxiga-May_2_16-e.pdf SR0445_Forxiga_CL_Report.pdf SR0445_Forxiga_PE_Report.pdf	Oct 23, 2018	Reimbursement Review		Complete	SR0445-000
Riociguat	cdr_SR0438_Adempas-PAH.pdf SR0438_complete_Adempas-Dec-21-15_e.pdf SR0438_Adempas_CL_Report.pdf SR0438_Adempas_PE_Report.pdf SR0438_Adempas_PI_Submissions.pdf	Oct 23, 2018	Reimbursement Review		Complete	SR0438-000
Blincyto for MRD-positive B-cell precursor ALL		Oct 16, 2018	Reimbursement Review		Withdrawn	PC0143-000